Enhancement of Electroluminescence by Low-Temperature Deposition of Organic Thin Solid Films

The electrical and light-emitting behaviors of electroluminescent cells,which consist of naphthoylimide(NPL)as emitting layer and poly(3-octylthiophene)(P3OT)doped with poly(N-vinylcarbazoe)(PVK)as hole transport layer sandwiched between indium-tin-oxide(ITO)and aluminum electrode,have been studied.The mixed polymer(P3OT:PVK)layer and the emitting layer were deposited by spin coating and by vacuum deposition respectively.It was found that the visible blue emission could be observed from the cells at low bias voltage.And when the ITO substrate was cooled to near the liquid N_(2) temperature during the deposition of NPL emitting layer,the brightness of the cell increased.It was confirmed that holes could be easily injected into NPL layer with deposition temperature decreased.

Surface Plasmon Resonance Investigations of Photoinduced Changes in Liquid Crystalline Azobenzene Polymer Langmuir-Blodgette Films

In this letter,we report a novel phenomenon of photoisomerization-induced changes in liquid crystalline azobenzene polymers P12 Langmuir-Blodgette monolayer deposited on gold film by irradiating the monolayer with UV(360nm)and blue(450nm)lights,which was investigated by surface plasmon resonance technique.It has been shown that it is possible to switch the refractive indices reversibly by irradiating these films with light of appropriate wavelength.

Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population

Background Dihydropyrimidine dehydrogenase （DPD）, a key enzyme involved in the catabolism of 5-fluorouracil （5-FU）, is the attractive candidate for pharmacogenetic research on efficacies and toxicities of 5-FU. The aim of this study is to explore the association between polymorphisms of dihydropyrimidine dehydrogenase gene （DPYD） and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in the Chinese population.

XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer

Background Platinum-based chemotherapeutics are the most common regimens for advanced non-small-cell lung cancer （NSCLC） patients, and genetic factors are thought to represent important determinants of drug efficacy. We prospectively assessed the status of the XPC Ala499Val and Lys939GIn gene polymorphisms and investigated whether these SNPs can predict the response to cisplatin/carboplatin-based regimens in advanced NSCLC patients in a Chinese population.Methods The treatment outcomes of 96 advanced NSCLC patients who were treated with platinum-based chemotherapy were evaluated. The polymorphic status of xeroderma pigmentosum group C （XPC） gene was genotyped by the 3-D polyacrylamide gel-based DNA microarray method.Results The distributions of XPC Lys939GIn genotypes differed significantly between the response group （complete ＋partial responses） and the non-response group （stable ＋ progressive disease; P=0.022）. The heterozygous A/C genotype carriers had a poorer response rate than the wild A/A genotype carriers in stage Ⅲ （OR, 0.074; 95% CI,0.008-0.704; P=0.023）. The XPC Ala499Val polymorphisms were not associated with response to platinum-based chemotherapy.Conclusion Polymorphisms of the XPC gene, Lys939GIn, may be a predictive marker of treatment response for advanced NSCLC patients in stage Ⅲ.

Association of polymorphisms of cytosine arabinoside- metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia

Background The cytosine arabinoside （Ara-C）-based chemotherapy is the major remedial measure for acute myeloid leukemia （AML）. Deoxycytidine kinase （DCK） and cytidine deaminase （CDA） are the key enzymes in the metabolism of Ara-C. Many single nucleotide polymorphisms （SNPs） and haplotypes of DCK and CDA, which contribute to susceptibility to Ara-C, have been identified in Africans and Europeans. However, there has been no report about the relation among three SNPs in DCK （rs115543896, rs72552079, and rs111454937） and two SNPs in CDA （rs2072671 and rs60369023）, and their clinical response to Ara-C for a Chinese population. In this study, we aimed to investigate whether these five SNPs are associated with the therapeutic outcomes of Ara-C-based chemotherapy regimens in patients with AML. Methods A total of 151 Chinese patients with AML were enrolled in our study. SNPs genotyping were performed using the MassARRAY system by means of the matrix-assisted laser desorption ionization-time of flight mass spectrometry （MALDI-TOF-MS） method. Results The results illustrated that DCKrs111454937 AA genotype was more frequent in patients with higher platelet count, and A allele frequency was significantly higher in the group 〈40 years, lower white blood cell （WBC） count patients group and the group with platelet counts 〉60xl0e/L. Meanwhile, both DCKrs72552079 TC （OR=1.225, 95% C1=1.225-9.851, P=0.0192） and CDArs60369023 GA （OR=9.851,95% C1=1.31-77.93, ,~=-0.0263） significantly improved Ara-C-based chemotherapy response. While DCKrs11554389 AA （OR=0.147, 95% CI=0.027-0.801, P=0.0267） was associated with the decrease of Ara-C-based chemotherapy response. Conclusion It is evident that the DCK and CDA polymorphisms might be the important markers for the AML patients＇ therapy outcomes in a Chinese population.